Introduction {#s1}
============

Routine early revascularization (REV)/early invasive strategy versus selective late revascularization (SLR)/ischemia-guided strategy are generally used to manage patients with unstable angina (UA) and non-ST-segment elevation myocardial infarction (NSTEMI) \[[@R01], [@R02]\]. However, superiority of either approach is still under debate with numerous studies and meta-analyses published over the last decade with different outcomes, limitations and clinical implications. Even the guidelines differ in their recommendations, with the European guidelines leaning towards REV and the AHA/ACC guidelines inclining towards both REV and SLR based on the appropriate patient population \[[@R01], [@R02]\]. So far, the most recent Cochrane meta-analysis published in 2016 showed appreciable risk reduction in refractory angina, myocardial infarction (MI) and re-hospitalization but no difference in all-cause mortality and death or nonfatal MI at 6 - 12 months with REV therapy \[[@R03]\]. However, over the past 2 years, results of long-term (10 - 15 year) follow-up of trials evaluating REV vs. SLR strategies have been published shedding light on potentially valuable long-term clinical outcomes. A close look and analysis of these trials together with previous results are particularly warranted. In addition, majority of these trials comparing these two strategies have been done either in Europe or the US/multicenter international trials. To date, no specific analysis has been done as to the effect of geographical location together with its implied differences in guideline-directed management.

Methods {#s2}
=======

Search strategy {#s2a}
---------------

We conducted a comprehensive search of five databases with human studies in any language from inception to June 2018. The databases included Ovid Medline In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid Embase, Ovid Cochrane Central Register of Controlled Trials, and Scopus. No language restriction was imposed, and only human studies were considered. The search strategy was designed and conducted by investigators. Controlled vocabulary, supplemented with keywords, was used to search for relevant studies. Search terms used were: "invasive strategy", "routine invasive strategy", "selective invasive strategy", "non-ST-segment elevation myocardial infarction", "unstable angina" and "acute coronary syndrome".

Study selection {#s2b}
---------------

Studies were included in this meta-analysis if they satisfied the following criteria: 1) The study design was prospective, randomized controlled trials (RCTs) comparing REV versus SLR strategy for UA/NSTEMI; 2) Studies providing desired outcomes, particularly revascularization, death and bleeding. We excluded reviews, editorials, non-human studies and studies without sufficient data. In addition, we excluded studies which included patients with NSTEMI, but not with desired outcomes. Studies of ST-segment elevation myocardial infarction and stable angina were also excluded.

Data extraction {#s2c}
---------------

Two authors (H.V. and C.K.) independently carried out data extraction using a standard extraction form. We extracted the following information from each study: authors, year of publication, study name, study location, years of follow-up, sample size (number of participants and incident cases), diagnostic criteria, participants' characteristics (age, gender and body mass index), length of follow-up, cardiovascular mortality, all-cause mortality, revascularization, and bleeding.

Quality assessment {#s2d}
------------------

Two authors (C.K. and H.V.) independently assessed the risk of bias for each study by using the modified Newcastle-Ottawa Scale (NOS). We resolved disagreements by discussion or by involving the co-authors to adjudicate and establish consensus. The quality of studies was no longer individually numerically quantified as all studies included were randomized controlled trials.

Statistical analysis {#s2e}
--------------------

We extracted or calculated relative risks (RR) and 95% confidence intervals (CI) from the included studies. For studies reporting odds ratios (ORs) or hazard ratios (HRs), as cardiovascular events were rare (\< 1%), HRs and ORs asymptotically approach RRs, and they were treated as RRs in the analysis. We converted RR to log transformed RR (logRR) and pooled the logOR from all the included studies using the DerSimonian and Laird random-effects method with the estimate of heterogeneity from the Mantel-Haenszel model. Exploratory random-effect meta-regression analyses were conducted to assess the influence of study characteristics (geographical location and type of study design) on study results. We also conducted subgroup analyses stratified according to the geographic location (region and country). The performances of subgroup-specific and statistical test of interactions among subgroups were assessed. Heterogeneity between the studies was evaluated using I^2^, in which \> 50% suggests substantial heterogeneity. Due to a limited number of studies included in each analysis and/or substantial heterogeneity, we could not evaluate potential publication bias. All statistical analyses were performed with Review Manager (RevMan) (computer program) (Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014), and test of proportions was performed using SPSS by IBM Build 1.0.0.903. All tests were two-sided with a significance level of 0.05. The meta-analysis has been reported in accordance with the Meta-analysis of Observational Studies in Epidemiology guidelines (MOOSE).

Results {#s3}
=======

Seventeen trials were included with a total of 15,812 patients. Out of 11 trials (7,783 patients) which were conducted in Europe, 3,975 patients were randomized to REV strategy and 3,808 patients were randomized to SLR strategy. Out of six trials (8,029 patients) which were conducted in the US/multicenter international trials, 4,112 patients were randomized into REV and 3,917 patients were randomized into SLR strategy. Average age of the patients included was 64.7 years (66 years in European and 61 years in US/international trials); 68% of patients were male. Average follow-up period of European and US/international trials was 43 months and 18.4 months, respectively. Baseline characteristics of European and the US/international trials are mentioned in [Table 1](#T1){ref-type="table"} \[[@R04]-[@R20]\]. Similarly, outcome characteristics of European and US/international trials are summarized in [Table 2](#T2){ref-type="table"} \[[@R04]-[@R20]\].

###### Baseline Characteristics of European and North American Trials \[[@R04]-[@R20]\]

                                     Authors                    Follow-up    Patients in REV group   Patients in SLR group   Age (yrs)   Male (%)   Diabetes mellitus (%)   Hypertension (%)
  ---------------------------------- -------------------------- ------------ ----------------------- ----------------------- ----------- ---------- ----------------------- ------------------
  European trials                                                                                                                                                           
    FRISC-II \[[@R04]\]              Wallentin et al (2016)     15 years     1,222                   1,235                   66          72         13                      30
    RITA-3 \[[@R05]\]                Hernderson et al (2015)    10.6 years   895                     915                     63          61         15                      35
    ITALIAN ELDERLY ACS \[[@R15]\]   Savonitti et al (2012)     12 months    154                     159                     81.8        49         38                      92
    ICTUS \[[@R06]\]                 Hoedemaker et al (2017)    10 years     604                     596                     62          74         14                      37
    ISAR COOL \[[@R16]\]             Neumann et al (2003)       1 month      203                     207                     70          66         26.1                    85.5
    LIPSIA NSTEMI \[[@R11]\]         Thiele et al (2011)        6 months     400                     200                     69          68         41                      82
    OPTIMA \[[@R19]\]                Riezebos et al (2009)      6 months     73                      69                      63          51         19                      53
    TRUCS \[[@R10]\]                 Michalis et al (2000)      12 months    76                      72                      62          76         29                      54
    VINO \[[@R20]\]                  Spacek et al (2002)        6 months     64                      67                      65.7        50         30                      60
    ABOARD \[[@R12]\]                Montalescot et al (2009)   1 month      175                     177                     65          72.6       21.7                    65.7
    ELISA \[[@R13]\]                 van't Hof et al (2003)     1 month      109                     111                     63          72         15                      45
  North American trials                                                                                                                                                     
    MATE \[[@R07]\]                  McCullough et al (1998)    21 months    111                     90                      57          77         11                      \-
    OASIS 5 \[[@R9]\]                Swahn et al (2009)         24 months    92                      92                      68.2        74         14                      62
    TACTUS TIMI 18 \[[@R17]\]        Cannon et al (2001)        6 months     1,114                   1,106                   60          65         28                      \-
    TIMACS \[[@R14]\]                Mehta et al (2009)         6 months     1,593                   1,438                   65          63.2       26.5                    \-
    TIMI IIIB \[[@R18]\]             Anderson et al (1995)      12 months    740                     733                     \-          66         \-                      \-
    VANQUISH \[[@R08]\]              Boden et al (1998)         23 months    462                     458                     62          97         24.9                    56.7

REV: routine early revascularization; SLR: selective late revascularization.

###### Outcome Characteristics of European and North American Trials \[[@R04]-[@R20]\]

                                      Group   Index hospital revascularization (%)   Total revascularized patients (%)   Total deaths (%)   Cardiac deaths (%)   Repeat MI during follow-up (%)   Rehospitalization due to ischemic heart disease (%)   CABG(%)
  ----------------------------------- ------- -------------------------------------- ----------------------------------- ------------------ -------------------- -------------------------------- ----------------------------------------------------- ---------
  European trials                                                                                                                                                                                                                                       
    FRISC \[[@R04]\]                  REV     76                                     82                                  38.7               14.3                 37.2                             \-                                                    \-
                                      SLR     14                                     58                                  39                 16                   45                               \-                                                    \-
    RITA-3 \[[@R05]\]                 REV     55                                     61                                  25.1               15.1                 \-                               \-                                                    21
                                      SLR     10                                     38                                  25.4               16.1                 \-                               \-                                                    4
    ITALIAN ELDERLY ACS \[[@R15]\]    REV     56                                     58                                  12.3               10.4                 7.1                              16                                                    7
                                      SLR     23                                     31                                  13.8               10.7                 10.7                             21                                                    2.5
    ICTUS \[[@R06]\]                  REV     \-                                     83                                  26.7               17.6                 18.9                             \-                                                    \-
                                      SLR     \-                                     61                                  23.7               15.2                 14.9                             \-                                                    \-
    ISAR COOL \[[@R16]\]              REV     78.3                                   \-                                  0                  \-                   6                                \-                                                    7.9
                                      SLR     72                                     \-                                  1.4                \-                   10.1                             \-                                                    7.7
    LIPSIA NSTEMI \[[@R11]\]          REV     84                                     \-                                  5.2                \-                   2.2                              28                                                    10
                                      SLR     70                                     \-                                  6.5                \-                   1                                9                                                     13
    OPTIMA \[[@R19]\]                 REV     \-                                     100                                 1                  \-                   3                                18                                                    \-
                                      SLR     \-                                     99                                  0                  \-                   4                                14                                                    \-
    TRUCS \[[@R10]\]                  REV     78                                     100                                 3.9                \-                   3.9                              13                                                    33
                                      SLR     38                                     61                                  12.5               \-                   4.2                              17                                                    18
    VINO \[[@R20]\]                   REV     \-                                     73                                  3.1                \-                   3.1                              2                                                     35
                                      SLR     \-                                     39                                  13.4               \-                   14.9                             2                                                     30
    ABOARD \[[@R12]\]                 REV     \-                                     80.1                                2.9                \-                   9.1                              12                                                    11
                                      SLR     \-                                     69.5                                1.1                \-                   4.5                              18.6                                                  11.3
    ELISA \[[@R13]\]                  REV     61                                     \-                                  3                  \-                   7                                \-                                                    14
                                      SLR     58                                     \-                                  5                  \-                   6                                \-                                                    19
  North American trials (Canada/US)                                                                                                                                                                                                                     
    MATE \[[@R07]\]                   REV     58                                     72                                  11                 \-                   6                                23                                                    18
                                      SLR     37                                     60                                  6                  \-                   2                                22                                                    11
    OASIS 5 \[[@R9]\]                 REV     57.7                                   64                                  8.8                \-                   12.9                             \-                                                    16
                                      SLR     30.4                                   51                                  2.2                \-                   13.3                             \-                                                    12
    TACTUS TIMI 18 \[[@R17]\]         REV     51                                     64                                  3.3                \-                   4.8                              11                                                    22
                                      SLR     36                                     45                                  3.5                \-                   6.9                              13.7                                                  16
    TIMACS \[[@R14]\]                 REV     74.4                                   93.1                                4.8                \-                   4.8                              1                                                     14.8
                                      SLR     68.7                                   77.2                                5.9                \-                   5.7                              3.3                                                   13.6
    TIMI IIIB \[[@R18]\]              REV     6                                      64                                  8.8                \-                   16.3                             26                                                    30
                                      SLR     19                                     58                                  9.9                \-                   15.4                             33                                                    30
    VANQUISH \[[@R08]\]               REV     44                                     \-                                  17.3               \-                   15.6                             \-                                                    20
                                      SLR     33                                     \-                                  13                 \-                   17.4                             \-                                                    19

Overall, there was no difference in all-cause mortality (RR: 1.01, 95% CI: 0.95 - 1.08, P = 0.7), MI (RR: 0.98, 95% CI: 0.79 - 1.22, P = 0.85) or coronary artery bypass grafting (CABG) (RR: 1.33, 95% CI: 0.92 - 1.91, P = 0.12) between REV and SLR strategy ([Figs. 1](#F1){ref-type="fig"}-[](#F2){ref-type="fig"}[3](#F3){ref-type="fig"}). There was however trend towards decreased incidence of MI in REV, 13.3% (1,029/7,704) vs. 15.1% (1,108/7,314) in SLR (P = 0.007) based on test of proportions analysis. In contrast, rate of CABG was higher in REV, 4.9% (140/2,831) vs. 3.7% (105/2,819) in SLR (P = 0.031). All of these trends however did not translate into significant effects based on the pooled risk ratios in the results of the meta-analysis ([Figs. 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}).

![Rate of all-cause mortality in routine early revascularization (REV) versus selective late revascularization (SLR) in randomized controlled trials conducted in Europe and the United States. Boxes represent the weight/effect size for each study; the diamonds reflect the pooled combined effect from the meta-analysis.](jocmr-10-12-868-g001){#F1}

![Rate of myocardial infarction (MI) after index hospitalization in routine early revascularization (REV) versus selective late revascularization (SLR) in randomized controlled trials conducted in Europe and the United States. Boxes represent the weight/effect size for each study; the diamonds reflect the pooled combined effect from the meta-analysis.](jocmr-10-12-868-g002){#F2}

![Rate of coronary artery bypass grafting (CABG) in routine early revascularization (REV) versus selective late revascularization (SLR) in randomized controlled trials conducted in Europe and the United States. Boxes represent the weight/effect size for each study; the diamonds reflect the pooled combined effect from the meta-analysis.](jocmr-10-12-868-g003){#F3}

In the US/international trials, incidence of all-cause mortality is much lower in REV 8.4% (390/4,624) vs. 22.8% (908/3,975) (P \< 0.001) in European trials ([Fig. 1](#F1){ref-type="fig"}); and in SLR 8% (359/4,421) vs. 24% (910/3,808) (P \< 0.001) based on the test of proportions analysis. However, this did not translate into significant changes in effects based on the pooled RR ratios in the meta-analysis even after subgroup analysis between US/international and European trials (P = 0.59, [Fig. 1](#F1){ref-type="fig"}). In the US/international trials, incidence of MI in either group was similar: 8.7% (406/4,624) in REV vs. 8.9% (396/4,421) in SLR (P = 0.8), whereas in European trials, REV had lower incidence of MI, 20% (623/3,080) vs. 25% (712/2,893) (P = 0.001), but no significant differences in the pooled RR ratios after subgroup analysis between US/international and European trials (P = 0.53, [Fig. 2](#F2){ref-type="fig"}). In US/international trials, rate of CABG was comparable between both groups, 2.7% (44/1,607) in REV and 2.3% (38/1,654) in SLR (P = 0.44), whereas in European trials, rate of CABG was higher in REV, 8.3% (96/1,144) vs. 5.7% (67/1,165) (P = 0.02), however, no significant differences in the pooled RR ratios after subgroup analysis between US/international and European trials (P = 0.42, [Fig. 3](#F3){ref-type="fig"}).

Discussion {#s4}
==========

We report an up-to-date meta-analysis comparing REV vs. SLR strategies opted for the treatment of UA/NSTEMI across the Atlantic. First, there was no difference in all-cause mortality rate of CABG and MI between REV and SLR strategies. Second, there was a trend of decreased incidence of MI and increased rates of CABG in the REV group, driven mostly by analogous trends in European trials. Third, in US/international trials, all-cause mortality was lower in REV group as compared to SLR group. These findings are consistent with a previous Cochrane analysis published in 2016 \[[@R03]\]. However, this prior analysis did not include the new long-term data from the FRISC-II \[[@R04]\], RITA-3 \[[@R05]\] and ICTUS \[[@R06]\] trials, which have been published recently.

In US/international trials, incidence of all-cause mortality in the REV group was lower than that in the European trials (8.4% vs. 22.8%), whereas incidence of MI and rates of CABG were similar in REV and SLR groups in the US/international trials. A potential explanation is that the US/international trials generally had shorter follow-up of about 1 year except for the MATE \[[@R07]\], VANQWISH \[[@R08]\] and OASIS-5 \[[@R9]\] trials which were up to 20 months, while the European trials had 10 to 15 years follow-up, garnering more mortality data. REV strategy had a trend of lower incidence of MI in European trials, in contrast to US/international trials where an increased incidence of MI was observed. An explanation for this was the significant heterogeneity in the US/international studies in terms of MI with the MATE trial skewing the results as it included subjects with ST-elevation MI in the analysis \[[@R07]\], and we were unable to extract or differentiate the date pertaining to only NSTEMI patients for this study, thus another explanation for the heterogeneity. In US/international trials, rate of CABG was comparable between both groups, whereas in European trials, rate of CABG was higher in the REV group. However, there was significant heterogeneity as the results are being skewed by the TRUCS study \[[@R10]\] wherein the investigators intentionally randomized patients to onsite balloon angioplasty plus emergency airlift for bypass surgery versus conservative medical treatment; thus, the higher rates of CABG. After exclusion of all these studies which skew the data, the likelihood of difference is small.

In looking for geographical differences in outcomes in REV versus SLR, we had to look at potential studies conducted in the US/international and Europe, including some old studies done before 2000, as some of them had the latest long-term follow-up data available for further analysis. However, the pitfall to this is that these studies may no longer be representative of contemporary standards of medical practice as a lot of progress has happened over the past 10 years. Some of the data derived is also limited by the natural differences in methodology such as the duration of follow-up, with most studies with 1 year or less follow-up duration, but several studies with 10 years or longer follow-up. As of now there is a mounting need to conduct more studies, this time incorporating most of the advances in guideline directed medical therapy including statins, newer antiplatelet agents as well as the highly sensitive troponin assays \[[@R21]\] and other new biomarkers. This is to help classify patients at a higher risk for which the evidence for benefit for REV was the highest based on the previous studies \[[@R22], [@R23]\]. In a different light, as some of the studies like the ICTUS \[[@R06]\] and LIPSIA-NSTEMI \[[@R11]\] trials involving only patients with positive troponin levels labeling them as higher risk showed no difference between REV and SLR strategies, therefore a better method of risk factor assessment and risk stratification which includes other variables is needed. There is a possibility that the previous trials did not fully capture the higher risk groups hence the ambiguous results; as recorded mortality rates have been lower compared to the large multinational registry GRACE cohort with mortality rates approaching about 12% at 6 months after discharge \[[@R24]\]. Another important limitation in interpretation is the differences in the timing of the invasive procedures. The ABOARD \[[@R12]\], ELISA \[[@R13]\] and TIMACS \[[@R14]\] trials tended to employ the invasive strategy earlier from as early as 70 min for the ABOARD trial to less than 24 h in the ELISA \[[@R13]\] and TIMACS \[[@R14]\] trials, while the delayed invasive group got it within 48 - 72 h. In comparison, in the old trials ICTUS \[[@R06]\], FRISC-II \[[@R04]\] and RITA-3 \[[@R05]\], SLR group got angiography only after certain criteria were met, such as recurrent symptoms or positive stress test. This can potentially alter results as meta-analyses have shown that an early invasive approach (within 24 h) resulted in reduced hospital stays, and reduced rates of bleeding, death, MI or stroke \[[@R25]\].

The rate of CABG was higher in the REV group. Studies that recruited their cohorts early such as RITA-3 \[[@R05]\] and FRISC II \[[@R04]\] had higher rates of CABG while lower rates were found in the newer studies such as LIPSIA-NSTEMI \[[@R11]\] and the Italian Elderly ACS study \[[@R15]\]. This is consistent with improving techniques/change in guidelines with increased use of high-risk and left main stenting in recent years. Another reason for the lower rate of CABG in the Italian Heart Study is also inclusion of a more elderly cohort (mean age: 81.8 years) which makes them less likely to be candidates for CABG.

It is also noted that there is a general trend of diminishing returns for benefits of the REV strategy. With the first meta-analysis done in 2006 with a mean follow-up of about 2 years, lower rates of all-cause mortality, non-fatal MI and rehospitalization for angina were noted with REV strategy \[[@R26]\]. This effect was still apparent but somewhat diminished with analysis of studies with subsequent 5-year follow-up, namely FRICS-II \[[@R04]\], RITA-3 \[[@R05]\] and ICTUS \[[@R06]\]. The only outcome significant in these studies was a composite of cardiovascular death and non-fatal MI with some trends towards less cardiovascular deaths and all-cause deaths \[[@R27]\]. Recently, the long-term outcomes of both the RITA-3 \[[@R05]\] trial and the ICTUS \[[@R06]\] trial have been published, both of which have a 10-year follow-up period. There was no benefit in all-cause mortality and cardiovascular mortality among patients who underwent the REV \[[@R05], [@R06]\]. In contrast, the FRISC-II trial analyzed the data differently. Although the difference in mortality was not sustained during the 15-year follow-up, they found that the REV delayed the occurrence of death or next myocardial infarction by as much as 18 months; the difference mainly driven by the postponement of new MI \[[@R04]\]. Some arguments for this difference in outcomes might be attributed to the fact that FRISC-II had the largest patient population, biggest difference in revascularization rates between groups and least crossover between both groups \[[@R04]\]. However, the role of diminishing returns of the REV strategy over the long term is still glaringly obvious. A possible explanation for this is that both the RITA-3 and FRISC-II studies recruited their patient population early, in an era where drug-eluting stent was used, and dual platelet antagonists were still not the norm \[[@R28]\]. The ICTUS trial recruited patients later from 2001 - 2003 but had a lot of crossover between REV and SLR groups which might have diminished the long-term benefit of REV \[[@R06]\]. To illustrate this point, coronary angiography during hospitalization was performed in 98%, 96% and 96% in the REV groups in ICTUS \[[@R06]\], FRISC-II \[[@R04]\] and RITA-3 \[[@R05]\], while it was performed in 53% of patients in ICTUS trial as compared to 7% and 16% FRISC-II and RITA-3 respectively, reflective of contemporary practice. These studies were also not powered enough to detect a long-term effect on all-cause mortality. Another proposition is that advances in medical care in general, including the use of newer drug eluting stents, newer antiplatelet agents, more adherence to guideline-directed therapy yielded further benefit for those in the SLR group closing the gap of benefit between the two groups. This includes the trend towards the use of better newer antiplatelet agents \[[@R29], [@R30]\], statins in the setting of ACS \[[@R31]\], the preferential use of radial approach for interventions \[[@R32]\], the now available second-generation drug-eluting stents \[[@R33]\], all of which contributed to an overall increase in favorable outcomes in management of acute cardiac ischemic events. This is evidenced by one study wherein an analysis of the GRACE cohort done on the trends between 1999 to 2006 revealed an increase in the use of beta blockers by 10%, statins by 40%, thienopyridines by over 50% while both angiography and percutaneous coronary intervention (PCI) rates increased by approximately 20% as well among NSTEMI and UA patients \[[@R34]\]. Consequently, this translated to a decrease in cardiogenic shock, heart failure, MI and death from discharge to the 6 months follow-up \[[@R34]\].

The findings of this meta-analysis should be interpreted with caution as the studies clumped together have high heterogeneity, specifically by the differences in follow-up. The studies with longer-term follow-up periods of 10 - 15 years like the FRISC-II \[[@R04]\], RITA-3 \[[@R05]\] and ICTUS \[[@R06]\] tend to have higher odds of mortality compared to the ones with shorter follow-up \[[@R12]-[@R14], [@R16]-[@R18], [@R34]\].

Conclusions {#s4a}
-----------

There was no statistical difference in all-cause mortality, MI or CABG in REV versus SLR strategy, even after analyzing trials across the Atlantic separately. Interestingly, trends of decreased all cause-mortality in REV were observed in US trials when compared to European trials. Furthermore, trends of decreased rate of MI and increased rate of CABG were observed in REV vs. SLR, likely driven by the results from European trials, which showed similar trends, whereas US/international trials showed comparable rates of MI and CABG. Still there is significant heterogeneity between studies and these findings should be interpreted with caution. Newer studies are warranted to reflect contemporary practice.
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